Tradestie Institutional Equity Comparison Engine

MESO vs CLDX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MESO Overall Edge

MESO Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Mesoblast Limited American Depositary Shares (MESO) driven by superior Growth & Margin, Options & Structure while CLDX counters with relative strength in Momentum & Technical. Fundamentally, MESO trades at N/M Forward P/E with -42.6% operating margin (+390.7% YoY revenue) versus CLDX at N/M Forward P/E and -211684.8% operating margin (-97.0% YoY). In options structure, MESO sits in UNCLASSIFIED (37th %ile IV; Dealer Gamma Walls on Pro) against CLDX sits in BREAKDOWN (56th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
MESO N/M vs CLDX N/M Fwd P/E
Growth & Margin Winner MESO
Op Margin -42.6% vs -211684.8% ยท YoY +390.7% vs -97.0%
Momentum & Technical Winner CLDX
1Y -16.4% vs +20.9% ยท 52W Pos 6% vs 28%
Options & Structure Winner MESO
UNCLASSIFIED (37th %ile IV) vs BREAKDOWN (56th %ile IV)
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
1M Return -6.1%
1Y Return -16.42%
Forward P/E N/M
Unified AI Score
34.6 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
CLDX NASDAQ
Celldex Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$28.68
-0.52% 1D
Market Cap $2.2B
1M Return +4.18%
1Y Return +20.91%
Forward P/E N/M
Unified AI Score
55.7 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 65.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MESO -16.42% CLDX +20.91% Spread: +37.33 pp (CLDX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MESO TTM Op. Margin: -42.6% CLDX TTM Op. Margin: -211684.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs CLDX. Trailing 12-month operating profitability (MESO -42.6% vs CLDX -211684.8%) and valuation multiples (MESO N/M vs CLDX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MESO (3) vs CLDX (5)
Institutional Metric MESO CLDX Criterion Row Winner
Market Capitalization Scale $1.7B $2.2B Larger Scale CLDX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +390.7% -97.0% Higher Growth MESO
Operating Margin (TTM) Profitability -42.6% -211684.8% Higher Margin MESO
Net Profit Margin Profitability -47.8% 0.0% Higher Margin CLDX
Return on Equity (ROE) Capital Efficiency -9.9% -49.5% Higher ROE MESO
52-Week Range Position Momentum 6% ($12โ€“$22) 28% ($22โ€“$45) Stronger Trend CLDX
Beta / 30D Volatility Risk Regime 1.18ฮฒ ยท 78% Vol 1.05ฮฒ ยท 45% Vol Lower Realized Risk CLDX
Unified Institutional Score Composite Signal 34.6 / 100 (SELL) 55.7 / 100 (HOLD) Higher Composite CLDX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MESO vs CLDX Buy Guide
MESO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 37th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MESO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CLDX BREAKDOWN
67d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 56th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CLDX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MESO nor CLDX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.